Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
On the AGM Presentation desks,If one would again look at slide 15, headlines for the diagnostic division and read the following line: “ Potential spin-out opportunity “, which clearly indicates to me that the company now have a better idea of how big and commercial the therapeutic division will be and hence the IPO, away from the diagnostic division.
The second half will no longer carry “if “ but “when” events will happen, which will completely revalue the company!
When Avacta, had their lab and office located in Cambridge, I always said that Avacta was the best thing out of Cambridge since Arm holdings.
Arm holdings now planning $60bill IPO, on the biotech side, let us see at what valuation Avacta’s upcoming IPO will be priced at, post announcements and any license deals.
If one re-read previous research notes, where the analyst would apply a” once we have AVA6000/AVA3996 and the FDA and successful trials” up and running, well then one would have a potential valuation, substantially above current estimates.
Let us hope it makes it to the IPO of the Therapeutic business before one of the majors moves on, with a multi billion dollar bid!
The large global healthcare companies are watching this one very closely.
With expected news flow ahead, no surprise early kick off in NY, watch BB on the bid and quietly picking up what they can get ,before a crowded book have to make attractive bids to get stock.No sellers above 100! A lively day ahead.
Would expect follow up buying this afternoon, the so called “shorts “ are getting rather rattled and we will see more “ I surrender “ trades later on, with size buyers picking up everything available at these levels, before we will have 40% upside and we will talk about this week’s trades as the easiest way of making substantial returns, the trick is : Never sell, as you will end up paying much more getting back in again.
We are all aware of the amazing progress we have seen with AVA6000 and AVA3996 and when the company does makes a Cohort update and indeed the FDA with fast tracking ref AVA6000 and the the very real possibility of a substantial license deal and fast tracking an IPO of the Therapeutic division. It is worth remembering when the company made the recent acquisition in the Diagnostic division of Coris, at the AGM, Avacta spoke of continuing to benefit from cross synergies across the division, which one would assume would include the cost savings benefits of halting the redevelopment of its own AffiDX SARS-CoV-2 antigen lateral flow test.
Cell therapy startup Turnstone adds to biotech IPO flurry with $80M raise
The offering is the fourth for the sector this month, the first time that’s happened in nearly a year and a half, according to BioPharma Dive data.